# REM-422

Source: https://onco.cc/drugs/rem-422/  
OnCo record `rem-422` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.

## Summary

REM-422 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Remix Therapeutics, in salivary gland cancers. Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: REM-422
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of REM-422: https://clinicaltrials.gov/search?intr=REM-422

## Connected records

- cancers: [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)
- trials: [Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma](https://onco.cc/trials/nct06118086/)

---
JSON: https://onco.cc/api/v1/entities/rem-422.json